Home
NewsNewsRenew Biotech confirms being a clinical testing provider for NOA Guide by Path Fertility, offering advanced evaluation for men with non-obstructive azoospermia, a form of male infertility.
Renew Biotechnologies, on January 29, 2025, went on to announce as Renew becomes clinical testing provider for NOA Guide by Path Fertility, which apparently is a newly launched epigenetic diagnostic test that is designed to inform surgical decision-making when it comes to men having non-obstructive azoospermia – NOA, which is a form of male infertility.
It is worth noting that the NOA Guide makes utmost use of the native-read sequencing technology by Renew so as to directly measure the epigenetic signals sans any sort of amplification or even chemical conversion and is enhanced so as to detect the quantifying sperm-derived cell-free DNA - cfDNA from the seminal samples.
The test is going to be processed by Wasatch BioLabs, which is a subsidiary of Renew and acts as the centralized core lab across all research and clinical sample processing. The test indeed addresses a long-standing gap when it comes to male infertility care. Patients having azoospermia most often than not go through surgical sperm retrieval, having limited ability to forecast if sperm are present or retrievable. Through identifying cfDNA signatures, which are associated with spermatogenesis, even at the time when the intact sperm are not observed, NOA Guide provides a minimally invasive way to evaluate the underlying production and also retrieval potential.
The collaboration has in it assay development and validation along with clinical-grade processing, helping with dependable epigenetic measurement, which is suitable for routine clinical usage with downstream effects when it comes to reproductive decision-making. According to co-founder & CEO Chad Pollard of Renew Biotechnologies, which is going to be the clinical testing provider for NOA Guide by Path Fertility, "Programs like NOA Guide reflect the type of diagnostic innovation we are focused on enabling. Our role is to help transform emerging biological insights into analytically sound, clinically operational tests through rigorous development and clinical processing."
Kristin Brogaard, PhD, Co-founder & CSO, Path Fertility, opines that "For men with non-obstructive azoospermia, the decision to pursue surgical sperm retrieval can be daunting and deeply personal. NOA Guide brings epigenetic insight earlier in the care journey, helping patients and clinicians approach these decisions with greater clarity and confidence."
Interestingly, the scientific foundation for the NOA Guide was created in partnership with academic researchers Dr. Tim Jenkins, Dr. Jonathon Hill, and Ryan Miller, as well as Dr. Ryan Barney, all from Brigham Young University, alongside major contributions coming in from the Path Fertility team’s Dr. Kristin Brogaard and Derek Petersen.
Through supporting diagnostic innovators such as Path Fertility, Renew Biotechnologies advances novel clinical applications that have come into existence through native-read sequencing, as Renew Becomes Clinical Testing–ready in its approach, enabling the partners to translate the biological insights that are emerging into analytically strong and clinically deployable diagnostics.
ARMS Embryo Watch offers time-lapse images of IVF embryos to patients by streaming each development stage and showing the output directly to the patient's device, enhancing transparency and emotional connection throughout the IVF journey.
Mochida Grants LG Chem Endometriosis Drug Licensing to develop and sell Dinagest that has an active ingredient, Dienogest, that halts endometrial cells from growing, offering a non-hormonal therapeutic option for women suffering from endometriosis.
Luna and Kindbody are redefining Intelligence in Fertility Care through a strategic partnership that integrates wearable biomarker tracking into clinical pathways. By capturing real-time physiological data, the collaboration enables personalised insights, enhances decision-making, and creates a more connected, data-driven fertility journey for patients and care providers alike.
The MOAA-Endorsed Bill for Fertility Challenges seeks to expand fertility care access for veterans by recognising infertility as a service-connected condition. By reducing barriers to IVF and treatment, the legislation addresses toxic exposure risks and aims to provide timely, equitable reproductive healthcare support for those who served.
Fairfax IVI expand donor sperm access through a strategic partnership that enhances availability, integrates donor services into fertility care, and supports diverse patient needs. With personalised guidance, genetic insights, and streamlined logistics, the collaboration aims to reduce barriers and deliver a more accessible, inclusive path to parenthood.
Sapyen and Avenues launch at-home fertility diagnostics, introducing a couple-first testing model in the UK. By integrating semen analysis and AMH testing into early care, this approach reduces clinic visits, accelerates diagnosis, and ensures balanced fertility evaluation, transforming how patients begin their reproductive health journey.
Nexpring Health has invested in May Health to accelerate the development of the Anavi™ System, a novel device designed to treat PCOS-Related Infertility. The technology aims to restore ovulation through a single office-based procedure, expanding treatment options for millions of women affected by polycystic ovary syndrome.
